Ignite Creation Date:
2025-12-25 @ 12:36 AM
Ignite Modification Date:
2026-02-21 @ 6:53 PM
Study NCT ID:
NCT02713867
Status:
COMPLETED
Last Update Posted:
2023-02-14
First Post:
2016-03-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-05-24
Start Date Type:
ACTUAL
Primary Completion Date:
2019-07-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-01-18
Completion Date Type:
ACTUAL
First Submit Date:
2016-03-11
First Submit QC Date:
None
Study First Post Date:
2016-03-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-03-10
Results First Submit QC Date:
None
Results First Post Date:
2020-06-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-18
Last Update Post Date:
2023-02-14
Last Update Post Date Type:
ACTUAL